| Project/Area Number |
18K15301
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Chonan Masashi 東北大学, 医学系研究科, 非常勤講師 (90813676)
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | CD40 / OX40 / 免疫療法 / 神経膠腫 / 免疫治療 / 腫瘍幹細胞 / PD-1 / 悪性神経膠腫 |
|---|
| Outline of Final Research Achievements |
Efficacy of immunotherapy using intravenous administration of anti-CD40 antibody in combination with intravenous administration of anti-PD-1 antibody was performed against rodent brain tumor model. Brain tumor mice were randomly assigned to 4 treatment groups; Group1 control, Group2 anti-CD40 antibody, Group 3 anti-PD-1 antibody, Group 4 combination. As a result, survival of mice in treatment groups 2 and 4, which received anti-CD40 antibody treatment, was significantly shorter than control as well as anti-PD-1 antibody group (p<0.05). In vivo imaging study performed simultaneously revealed rapid growth of tumors in group 2 and 4 confirming the result of survival study. Analysis of tumor infiltrating immune cells is now on-going. We are also planning another survival study using vaccination, i.e. subcutaneous administration of anti-CD40 antibody and/or anti-PD-1 antibody in combination with tumor lysate based subcutaneous vaccine and evaluate the difference in efficacy.
|
| Academic Significance and Societal Importance of the Research Achievements |
膠芽腫を代表とした悪性神経膠腫の治療成績は、現時点での外科的摘出術、化学療法、放射線治療を用いても依然として絶対的に不良であり、第4の治療法として注目されている免疫治療の開発が急務とされている。近年、悪性神経膠腫の治療抵抗性には腫瘍幹細胞が関与しているとされ、我々は免疫共剌激因子であるCD40（樹状細胞やB細胞活性化し間接的に抗腫瘍効果を発揮するとともに、腫瘍細胞に対しては直接的にアポトーシスを誘発）の刺激抗体を用いた免疫治療の開発を目指して研究を進めている。
|
